Navigation Links
Nventa updates progress of cervical dysplasia trial with new HspE7
Date:10/18/2007

release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the number of cohorts and patients and the expected dosing amounts in the Phase 1 trial; successful completion of the Phase 1 trial; the launching of a Phase 2 clinical trial in patients with high-grade cervical intraepithelial neoplasia (CIN2/3); the possibility of a second Phase 2 trial in HIV-positive low-grade CIN patients.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that we will not be able to recruit patients for our trials in a timely manner; our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials: our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. Wisconsin cities make progress on wireless Internet coverage
6. Doyle laments lack of progress on stem cell bill
7. U.S. health system could undermine EHR progress
8. Stem-cell controversies slow progress
9. VC trends, company progress discussed at Mason Wells portfolio meeting
10. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
11. Furious pace of Midwest biotech events marks progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... Hungary , September 30, 2014 ... and intuitive browsing of chemistry in documents ... chemistry software solutions and consulting services for life ... chemical information and generate Markush structures from documents. ... an organizations intellectual property, however generating and understanding ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
(Date:9/30/2014)... Md., Sept. 30, 2014 BioHealth Innovation, ... commercializing market-relevant biohealth innovations and increasing access to early-stage ... today that venture capitalist, Tania Fernandez , Ph.D., ... Dr. Fernandez will be a member of the management ... provide up to $50 million in seed and early-stage ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... , ... , , , Antibodies ... arrays) or as biopharmaceutical therapeutics. In,all cases the successful production ... criteria include: protein identification,quantitation and the monitoring of purity and ...
... , ... , , , ... of the Agilent 2100 bioanalyzer in combination,with the Protein 200 Plus ... denaturing gel-elctrophoresis (SDSPAGE).,The results showed that the Agilent 2100 bioanalyzer provides,fast ...
... , ... , , , , ... an siRNA sequence,for a target gene, which are of,high importance ... crucial.,An efficient method to optimize,transfection and gene silencing,is critical for ...
Cached Biology Technology:Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 2Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 3Comparison of different protein,quantitation methods 2Comparison of different protein,quantitation methods 3Comparison of different protein,quantitation methods 4Comparison of different protein,quantitation methods 5Comparison of different protein,quantitation methods 6Comparison of different protein,quantitation methods 7Comparison of different protein,quantitation methods 8Comparison of different protein,quantitation methods 9Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 2Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 3Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 4
(Date:9/30/2014)... Salk professor and Howard Hughes Medical Institute investigator, ... named recipients in the 2014 round of grants ... the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... announced September 30, provides more than $3 million ... years. , The BRAIN Initiative, launched last year, ...
(Date:9/30/2014)... water may increase the risk of stillbirth and ... by a Boston University School of Public Health ... Environmental Health , compared 1,091 PCE-exposed pregnancies ... Cape Cod, Ma., where water was contaminated in ... the installation of vinyl-lined asbestos cement pipes. PCE ...
(Date:9/30/2014)... live in almost any aquatic environment on Earth, but ... species are pushed to the limit. The amount of ... critical for how different species cope in the future, ... of Gothenburg, published in the scientific journal Proceedings ... continues apace thanks to increasing levels of greenhouse gases ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2
... in ecological or environmental conservation remains contentious the ... demand that governments regulate and encourage restoration projects; ... corporations makes such interventions politically difficult. However, ... a handful of developing nations, alongside South Africa, ...
... , RIVERSIDE, Calif. Alan McHughen , a ... University of California, Riverside, has been chosen by the ... Sciences to receive a 2011-2012 Jefferson Science Fellowship ... selected for the fellowships this year. Successful ...
... is redefining the rules by which we live and at ... level, several areas of the globe are in danger of ... and maybe, one day, live in floating houses. Depending ... others in their adjustment to the effects of global warming, ...
Cached Biology News:UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 2UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 3Floating houses 2Floating houses 3
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... 20-HETE is a cytochrome P450 (CYP450) metabolite ... the renal and cerebral vasculature. In rat ... mediates pressure-induced autoregulatory vasoconstriction. 20-HETE is excreted ... of free 20-HETE (20-40 pg/ml in human ...
... GPS-M Mutagenesis System enables you to insert ... into,your target DNA by in vitro transposition. ... Tn7-based,transposon randomly into the DNA target. Target ... or purified,chromosomal DNA, depending on your interests ...
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: